Physician profile
Clement Chan
NPI 1063601904
$2,730.09
in general payments reported to CMS, 2019-2025
25 companies · $1,197 in 2025
The $1,197 reported for 2025 was more than what 83% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $741 · 2022: $204 · 2023: $156 · 2024: $433 · 2025: $1,197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,766 · Education: $20.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,765.58 |
| Education | $20.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $458.54 | 2024-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $354.94 | 2021-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $353.48 | 2021-2025 | |
| Pfizer INC. | $220.54 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $199.47 | 2021-2025 | |
| Amgen INC. | $139.04 | 2022-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $125.54 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $122.85 | 2021-2024 | Farxiga |
| Harrow Eye, LLC | $89.47 | 2023 | Natacyn, Tobradex St, Iheezo |
| Esperion Therapeutics, INC. | $88.44 | 2021 | |
| Amarin Pharma, INC. | $84.89 | 2021 | |
| Abbott Laboratories | $78.86 | 2022-2025 | Cardiomems |
| Kestra Medical Technology Services, INC. | $65.96 | 2025 | Assure Wcd |
| Actelion Pharmaceuticals US, INC. | $44.46 | 2025 | Uptravi, Opsynvi, Opsumit |
| Abiomed | $44.05 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $40.59 | 2022-2024 | Camzyos |
| Arbor Pharmaceuticals, INC. | $36.44 | 2021 | |
| Alnylam Pharmaceuticals INC. | $35.81 | 2025 | Amvuttra |
| Boston Scientific Corporation | $32.55 | 2022 | |
| Lantheus Medical Imaging, INC. | $29.50 | 2023 | Definity |
| Impulse Dynamics (USA) INC. | $27.75 | 2024 | Optimizer |
| Lexicon Pharmaceuticals, INC. | $18.37 | 2024 | |
| Xeris Pharmaceuticals, INC. | $17.81 | 2021 | |
| Amryt Pharma Holdings LTD | $15.13 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $5.61 | 2025 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clement Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.